Navigation Links
FDA Sets April 24, 2012 as PDUFA Goal Date for Cell Therapeutics' Resubmitted Pixantrone New Drug Application
Date:12/6/2011

sed or refractory NHL and/or other tumors as determined by the FDA and/or the EMA, that accelerated approval by the FDA of pixantrone may not occur, that CTI may not be able to address satisfactorily the two key matters raised by the OND or other matters raised by the DOP1, the OND and/or the FDA, that CTI's interpretation of the guidance provided by the OND, the DOP1 and/or the FDA may be different than the intent of the OND, the DOP1 and/or the FDA, that the OND, the DOP1 and/or the FDA may change its guidance, that the PIX301 study may not be deemed successful, that upon a re-review and/or resubmission of the NDA the FDA may find pixantrone to not be safe and/or effective, that the PIX301 study may still be deemed to be a failed study, that the FDA may require an additional clinical trial of pixantrone, that if CTI conducts an additional clinical trial, it may not demonstrate the safety and effectiveness of pixantrone, that CTI may not be able to provide satisfactory information in response to the CRL, that the FDA may not complete the review of the NDA by the PDUFA goal date of April 24, 2012, that the CHMP may not render an opinion on CTI's application for pixantrone with the EMA by January 19, 2012, CTI's ability to continue to raise capital as needed to fund its operations, competitive factors, technological developments, costs of developing, producing and selling pixantrone, and the risk factors listed or described from time to time in CTI's filings with the Securities and Exchange Commission including, without limitation, CTI's most recent filings on Forms 10-K, 10-Q and 8-K. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

Media Contact:

Dan Eramian
T: 206.272.4343
C: 206.854.1200
E: deramian@ctiseattle.com

Investors Contact:
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Alseres Pharmaceuticals, Inc. to Address a Congressional Briefing on Paralysis Research and the Spinal Cord Injury Community at Working 2 Walk in Washington, DC, April 13-15, 2008
2. ViroPharma to Release 2008 First Quarter Financial Results on April 30, 2008
3. April 16th Congressional Hearing on Hospital Infections
4. The COSHAR Foundation Launches National Childhood Immunization Awareness Campaign During National Infant Immunization Week (April 19-26)
5. PharmAthene to Host a Conference Call and Webcast on Wednesday, April 29th at 4:30 PM to Provide an Update on the SparVax(TM) rPA Anthrax Vaccine Program
6. FDA Sets Action Date of April 23, 2010 for Review of Pixantrone NDA
7. 2nd Annual Orthopedic Design & Technology Forum Returns April 28 to the FedEx Institute of Technology, University of Memphis
8. Stryker to Host Conference Call on April 20, 2010
9. FDA Consumer Health Information - Generic Drug Roundup: April 2010
10. United Therapeutics Corporation To Announce First Quarter 2010 Financial Results Before Market Open on Thursday, April 29, 2010
11. CardioGenics to be Spotlighted in Three Publications During Month of April
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... , Jan. 14, 2014 The Brandeis Medical Center, led ... a premier and affordable laser tattoo removal experience with ... Brandeis, focus is in providing high quality cosmetic services with cutting ... " Southern California has seen a ...
(Date:1/14/2014)... , Jan. 14, 2014 Animal Emergency Critical Care, a LifeCentre ... Leesburg, Virginia is the first in Loudoun ... Dr. Susan M. Barnes , Medical Director, ... and husband, Dr. Cole Taylor , are avid scuba divers. ...
(Date:1/14/2014)... , Jan. 14, 2014   Oligomerix, Inc. , a ... therapeutics for Alzheimer,s disease (AD) and related neurodegenerative disorders, ... Valhalla, NY as of January ... space at New York Medical College. Oligomerix, ...
Breaking Medicine Technology:Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2
... ANTONIO, Feb. 28, 2011 Advanced Cell Diagnostics, ... clinical study utilizing RNAscope™ technology to detect human ... of head and neck cancer. HPV status determined ... of patient outcome and highly concordant with that ...
... 2011 PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI ) ... dividend policy for 2011 and beyond and declared that the four ... be $0.15 per share of common stock.  The $0.15 dividends will ... 15 to all stockholders who own shares of PDL on March ...
Cached Medicine Technology:ACD Announces Clinical Study Results Using its RNAscope™ Technology 2ACD Announces Clinical Study Results Using its RNAscope™ Technology 3PDL BioPharma Announces Regular Quarterly Dividend Policy 2
(Date:4/18/2014)... Medicine scientists could lead to potential new treatments for ... scleroderma. , Fibrosis, or scarring, is a hallmark ... and lungs can lead to serious organ damage and, ... therapeutic options centers on findings made by Swati Bhattacharyya, ... role that a specific protein plays in promoting fibrosis. ...
(Date:4/17/2014)... relief targets that could be used to provide ... College London made the discovery when researching how ... the body. , Dr Marzia Malcangio said: "We ... generation and our findings could help chemotherapy patients ... potential side effect of some chemotherapy drugs (such ...
(Date:4/17/2014)... the University of California, San Diego School of Medicine ... have suffered a recent major loss are more likely ... , The study is published in this month,s issue ... , Because compassionate behaviors are associated with better health ... insights into ways to improve the outcomes of individuals ...
(Date:4/17/2014)... biology team has created a new technology for ... could travel the body and selectively target cancer ... biological devices that monitor and modify human physiology ... However, no existing technology enabled bioengineers to build ... and respond in a customized fashion. , "The ...
(Date:4/17/2014)... (April 16, 2014) The cause of neuronal death ... study proposes that neurons may be mistaken for foreign ... similar to the way autoimmune diseases like type I ... cells. The study was published April 16, 2014, in ... and likely controversial, idea in Parkinson,s disease; but if ...
Breaking Medicine News(10 mins):Health News:New clues on tissue scarring in scleroderma 2Health News:New pain relief targets discovered 2Health News:The ilk of human kindness 2Health News:Building 'smart' cell-based therapies 2Health News:Is Parkinson's an autoimmune disease? 2
... 2 Bob Hickman, United Feather & Down,s Senior Vice ... Inc.,s Vice President of Marketing, list their top sleep and ... four times faster than water, and its super emollient qualities ... bedding is kind to your skin to help you awaken ...
... , MIAMI, Oct. 2 The American Lung Association of ... Influenza initiative by conducting a public influenza panel discussion ... influenza and the importance of annual vaccination. The meeting will ... among high-risk groups. , The recent A (H1N1) outbreak ...
... Rising Medical Solutions, Inc. (Rising), a leading medical-financial solutions ... Company Index (PCI) "Top 10 Growth Companies" list. This ... honoree, making it the longest running Company to achieve ... , Comments Stephen H. Watkins, CEO of PCI sponsor ...
... , LEE,S SUMMIT, Mo., Oct. 2 R&D/Leverage,s ... integrated under one roof - continue to expand in ... the company,s Vice President - Engineering. , According to ... technical and engineering staff, new lean initiatives and quality-control ...
... LAS VEGAS, Oct. 2 Cord Blood America, Inc. ... cell preservation company ( http://www.cordblood-america.com ) ... cells, a biological insurance policy, to families nationwide and ... principal amount $160,000, in its continuing effort to reduce ...
... World Vision, one of the world,s leading emergency response ... be a wake-up call to the global community to fund ... agency, an expert in disaster risk reduction (DRR), works with ... to disasters like earthquakes and tsunamis, and says that DRR ...
Cached Medicine News:Health News:Ten from Two: Top Sleep and Beauty Tips from the Experts 2Health News:Ten from Two: Top Sleep and Beauty Tips from the Experts 3Health News:American Lung Association of Florida-South Area Encourages Miami Residents to See Themselves Among the Many 'Faces' of Influenza 2Health News:American Lung Association of Florida-South Area Encourages Miami Residents to See Themselves Among the Many 'Faces' of Influenza 3Health News:American Lung Association of Florida-South Area Encourages Miami Residents to See Themselves Among the Many 'Faces' of Influenza 4Health News:American Lung Association of Florida-South Area Encourages Miami Residents to See Themselves Among the Many 'Faces' of Influenza 5Health News:Rising Medical Solutions First to Achieve Six Consecutive Rankings on the Private Company Index 2Health News:R&D/Leverage Heightens Investment in Medical and Silicone Mold Manufacturing 2Health News:R&D/Leverage Heightens Investment in Medical and Silicone Mold Manufacturing 3Health News:Cord Blood America Retires Note in Continuing Effort to Reduce Debt 2Health News:World Vision Says Asian Disasters Should Be 'Wake-Up Call' For Global Leaders 2Health News:World Vision Says Asian Disasters Should Be 'Wake-Up Call' For Global Leaders 3
... SST™ Tubes contain spray-coated ... gel for serum separation. ... serum determinations in chemistry. ... efficient means of serum ...
BD Vacutainer® PST™ Tubes contain spray-coated lithium heparin and a gel for plasma separation. They are used for plasma determinations in chemistry....
MONOJECT Red/Yellow Mottled Stopper...
BD Vacutainer® Specialty Tubes - Thrombin...
Medicine Products: